Company News

Hoth Therapeutics, Weill Cornell Extend Acne Research

Investigating mechanism of action and safety of novel novel retinoic acid metabolism blocking agent.

Author Image

By: Christine Esposito

Editor-in-Chief

Biopharma company Hoth Therapeutics, Inc. is extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA) for the treatment of acne. The single year agreement extension is based on positive results generated from a prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.

The extended collaboration will expand the scope of investigation to further understand the therapeutic mechanism of HT-003 for treatment of acne and other inflammatory skin diseases. The research will also explore safety of HT-003 in murine models. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and HOTH Senior Scientific Advisor, will be the Principal Investigator for the research collaboration. 

According to Hoth, its pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne and other immunological disorders.

Keep Up With Our Content. Subscribe To Happi Newsletters